Pellizzari, Sierra
Bhat, Vasudeva
Athwal, Harjot
Cescon, David W.
Allan, Alison L.
Parsyan, Armen
Funding for this research was provided by:
Ontario Graduate Scholarship
Breast Cancer Society of Canada
Western Postdoctoral Fellowship
London Regional Cancer Program Catalyst Grant
Young Investigator Startup Grant, Department of Surgery, Western University and the London Regional Cancer Program Catalyst Grant for Translational Cancer Research, Western University
Cancer Research Society (CRS) and Canadian Institutes of Health Research (CIHR)/Institute of Cancer Research (ICR), Operating Grants 2022 Competition, Targeted Funding Opportunity
Clinician Scientist Award, Department of Surgery, Western University, and the Academic Medical Organization of Southwestern Ontario (AMOSO) Opportunities Fund
Article History
Received: 15 June 2023
Accepted: 18 January 2024
First Online: 16 February 2024
Declarations
:
: The study was conducted in accordance with the Declaration of Helsinki and approved by the Institutional Review Board (or Ethics Committee) of Western University (protocol codes 118685 (30/Mar/2021); 118019 (25/Jan/2021)).
: D.W.C. reports advisory services to AstraZeneca, Exact Sciences, Eisai, Gilead, GlaxoSmithKline, Inivata, Merck, Novartis, Pfizer, and Roche; reports research funding (to institution) from AstraZeneca, Gilead, GlaxoSmithKline, Inivata, Merck, Pfizer, and Roche; is a member of a trial steering committee for AstraZeneca, Merck, and GlaxoSmithKline; and D.W.C. holds a patent (US62/675,228) for methods of treating cancers characterized by a high expression level of spindle and kinetochore associated complex subunit 3 (<i>SKA3</i>) gene.